Home
/
Cocrystal Pharma, Inc.
/
Financials
/
Quarterly
Cocrystal Pharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Cocrystal Pharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2021
Jun 30, 2020
$554.0K
Aug 16, 2021
Q1
2016
Mar 31, 2016
$0
May 10, 2016
Q3
2016
Sep 30, 2015
$24.0K
Nov 9, 2016
Q2
2016
Jun 30, 2015
$27.0K
Aug 9, 2016
Q1
2016
Mar 31, 2015
$27.0K
May 10, 2016
Q1
2014
Mar 31, 2014
$733.0K
May 15, 2014
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2021
Sep 30, 2020
$489.0K
Nov 15, 2021
Q2
2021
Jun 30, 2020
$554.0K
Aug 16, 2021
Q1
2021
Mar 31, 2020
$461.0K
May 17, 2021
Q3
2020
Sep 30, 2019
$492.0K
Nov 13, 2020
Q2
2020
Jun 30, 2019
$592.0K
Aug 6, 2020
Q1
2020
Mar 31, 2019
$5.08M
May 13, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($2.05M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($2.06M)
Aug 14, 2025
Q3
2025
Jun 30, 2025
($2.06M)
Nov 14, 2025
Q3
2025
Mar 31, 2025
($2.30M)
Nov 14, 2025
Q2
2025
Mar 31, 2025
($2.30M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($2.30M)
May 15, 2025
Q3
2025
Sep 30, 2024
($4.94M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($5.34M)
Aug 14, 2025
Q3
2025
Jun 30, 2024
($5.34M)
Nov 14, 2025
Q2
2025
Mar 31, 2024
($3.96M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($3.96M)
May 15, 2025
Q3
2025
Mar 31, 2024
($3.96M)
Nov 14, 2025
Q3
2024
Sep 30, 2023
($4.17M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($4.17M)
Aug 14, 2024
Q3
2024
Jun 30, 2023
($4.17M)
Nov 13, 2024
Q3
2024
Mar 31, 2023
($5.19M)
Nov 13, 2024
Q2
2024
Mar 31, 2023
($5.19M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($5.19M)
May 13, 2024
Q3
2023
Sep 30, 2022
($5.70M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($24.43M)
Aug 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($2.09M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($2.11M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($2.34M)
May 15, 2025
Q3
2025
Sep 30, 2024
($5.04M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($5.45M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($4.16M)
May 15, 2025
Q3
2024
Sep 30, 2023
($4.44M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($4.34M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($5.11M)
May 13, 2024
Q3
2023
Sep 30, 2022
($5.69M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($24.43M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($4.21M)
May 15, 2023
Q3
2022
Sep 30, 2021
($3.95M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($3.83M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($2.74M)
May 11, 2022
Q3
2021
Sep 30, 2020
($2.71M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($3.45M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($1.96M)
May 17, 2021
Q3
2020
Sep 30, 2019
($1.81M)
Nov 13, 2020
Q2
2020
Jun 30, 2019
($1.55M)
Aug 6, 2020